Clinical trials: POAG
Primary Open Angle Glaucoma
Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)
The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.
- Trial name
- NCT07048886
- Testing
- Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Center for Sight Las Vegas
Primary Open Angle Glaucoma
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on…
- Trial name
- NCT04396002
- Testing
- Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative
Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.
The objective of this study is to demonstrate the ability of the Hydrus Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative, Cataract Unilateral Pending Extraction
- Trial name
- Hydrus II (NCT01818115)
- Testing
- Hydrus Implant, IOL placement
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 100 people
- Sponsor
- Ivantis, Inc.
Glaucoma, Primary Open Angle, Cataract
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent…
- Trial name
- NCT04465864
- Testing
- Intracanalicular Dexamethasone, 0.4 mg insert
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wolstan and Goldberg Eye Associates
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
This study will evaluate the safety and efficacy of PF 03187207.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT00441883
- Testing
- PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
- Where
- 19 sites in United States
- Volunteers
- 176 people
- Sponsor
- Bausch & Lomb Incorporated
Eye Diseases, Glaucoma, Open-Angle
Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)
Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.
- Conditions
- Eye Diseases, Glaucoma, Open-Angle, Glaucoma
- Trial name
- SL (NCT00913029)
- Testing
- iStent, latanoprost/timolol
- Where
- 16 sites in Armenia, Austria and 7 more
- Volunteers
- 192 people
- Sponsor
- Glaukos Corporation
Primary Open-Angle Glaucoma (POAG)
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.
- Trial name
- NCT06437639
- Testing
- Mexidol
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Pharmasoft
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult…
- Trial name
- MATrX-1 (NCT02565173)
- Testing
- trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Obstructive Sleep Apnoea, Primary Open-angle Glaucoma
PAIR Study-PAP And IOP Relationship: Study 2
Some people with Primary Open-angle Glaucoma (POAG) also suffer from Obstructive Sleep Apnoea (OSA), a common sleep disorder which is known to affect heart and blood vessels, and may contribute to glaucoma progression.
- Trial name
- PAIR2 (NCT03145129)
- Testing
- Continuous Positive Airway Pressure
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Glaucoma, Primary Open Angle Glaucoma
Ahmed Glaucoma Valve Surgery With Mitomycin-C
This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half…
- Conditions
- Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
- Trial name
- AMCT (NCT02805257)
- Testing
- Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant
- Where
- 4 sites in United States, China and 2 more
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Glaucoma, Glaucoma, Open-Angle
Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor
- Trial name
- NCT05127551
- Testing
- iStent Infinite, Competitor Device
- Where
- Canada
- Volunteers
- 179 people
- Sponsor
- Glaukos Corporation
Primary Open-angle Glaucoma
Impact of Glaucoma and Visual Field Loss on Life Space
Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on…
- Trial name
- NCT03673644
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Alabama at Birmingham
Primary Open Angle Glaucoma, Ocular Hypertension
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
- Trial name
- NCT00595101
- Testing
- PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle
- Where
- 13 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open-angle Glaucoma
Effects of Primary Open-angle Glaucoma on Visual-motor Coordination
Commonly used visual function assessments in glaucoma diagnosis and treatment-such as visual acuity, visual field, and contrast sensitivity-do not directly capture the impact of the disease on patients' daily abilities.
- Trial name
- NCT06692205
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Primary Open Angle Glaucoma
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are…
- Trial name
- NCT05695027
- Testing
- Dietary supplements - Nicotinamide and Pyruvate
- Where
- 3 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Columbia University
Primary Open-Angle Glaucoma (POAG)
Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma
This study evaluates whether a personalized mobile reminder program improves treatment adherence and clinical outcomes in adults with primary open-angle glaucoma (POAG) using topical antiglaucoma eye drops.
- Trial name
- M-GLAUCO (NCT07480577)
- Testing
- Digital Reminder Intervention
- Volunteers
- 84 people
- Sponsor
- Sakarya Yenikent State Hospital
Glaucoma, Open-Angle, Ocular Hypertension
GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3…
- Trial name
- NCT01628601
- Testing
- Fixed combination 0.3 mg bimatoprost and 5 mg timolol
- Where
- Austria
- Volunteers
- 392 people
- Sponsor
- Allergan
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH